Insilico Medicine Earns Accolades from Frost & Sullivan for Its Pioneering R&D in AI for Aging Research and Drug Discovery
The company has leveraged its expertise in Artificial Intelligence, Big Data analytics, and blockchain to create an ecosystem of cutting-edge solutions to support R&D for aging-related products and solutions
LONDON, June 19, 2018 /PRNewswire/ -- Based on its recent analysis of the North American market for artificial intelligence (AI) for aging research and drug development, Frost & Sullivan recognizes Insilico Medicine with the 2018 North American Technology Innovation Award. The company's AI-based platform bridges biology and chemistry and digital health. It connects genomic, metabolomic, proteomic, and other clinical databases and then analyzes the data to find pathologically activated pathways. In turn, these can aid in the creation of actionable targets for age management and the company generates novel molecules for these specific biological targets using the Generative Adversarial Networks and Reinforcement Learning (GAN-RL) techniques. Insilico Medicine has shown visionary capabilities in understanding the aging-related technology needs of academia, pharmaceutical companies, dietary supplement manufacturers, and cosmetics companies.
Photo - https://mma.prnewswire.com/media/707028/Insilico_Medicine_Award_Logo.jpg
"Insilico Medicine employs unique methodologies for aging R&D, such as the 'in silico Pathway Activation Network Decomposition Analysis (iPANDA), for analyzing signaling and metabolic pathway perturbation states," said Neelotpal Goswami, Senior Industry Analyst. "It studies the effects of external perturbations on the activation of signaling pathways and their effect on downstream targets. This offers clinicians a clearer understanding of the ways in which genes involved in age-related diseases and cancers are dynamically controlled by complex networks of signaling pathways."
Insilico Medicine uses parallel, high-performance, AI-enabled computing solutions for in silico drug discovery and drug repurposing for multiple diseases, including cancer, age-related diseases, neurodegenerative diseases, and fibrosis. To keep its lead in aging-focused R&D, the company has collaborated with a number of leading research-based universities around the world, like the University of Copenhagen, to develop drugs to treat Alzheimer's, Parkinson's, and cardiovascular diseases. The company also has an alliance with Gachon University and the Gil Medical Center in South Korea to develop multimodal aging biomarkers as well as interventions intended to slow down age-related loss of function. The company collaborates with WuXi AppTec to validate novel targets and molecules discovered using its next-generation AI pipelines. WuXi AppTec, Pavilion Capital/Temasek Holdings, BOLD Capital Partners and Juvenescence are among the strategic investors in Insilico Medicine.
Meanwhile, the company is working on multiple projects that leverage its core AI expertise in diverse areas. For example, it offers an AI-powered digital health platform named Young.AI that helps users track health-related parameters over time to better manage healthy aging by integrating multiple predictors of a person's age. Young.AI enables testing and real-life performance evaluation of these predictors. Another significant digital tool from the company is the Nutriomi personalized nutrition management platform for healthy aging. It employs an omics-informed personalized approach to nutrition, wherein scientific data is used to match personal preferences and needs of healthy nutrition for longevity.
"Technology leadership in artificial intelligence for drug discovery and biomarker development, academic excellence, extensive collaborations with pharmaceutical and consumer companies, novel methods of attracting top talent, and increasing global reach have allowed Insilico Medicine to build a credible and sustainable business model in the nascent longevity biotechnology industry," noted Neelotpal Goswami. "In recognition of its pioneering research and ability to introduce novel products and solutions for age management, Frost & Sullivan is pleased to present it with the 2018 Technology Innovation Award."
Each year, Frost & Sullivan presents this award to the company that has developed a product with innovative features and functionality that is gaining rapid market acceptance. The award recognizes the quality of the solution and the customer value enhancements it enables.
Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.
About Insilico Medicine, Inc.
Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan, and Korea sourced through hackathons and competitions. The company and its scientists is dedicated to extending human productive longevity and transforming every step of the drug discovery and drug development process through excellence in biomarker discovery, drug development, digital medicine and aging research. Insilico Medicine's work was recently covered by MIT Technology Review China, Nature Medicine, Nature Biotechnology, The Pharmaceutical Journal and many others. The Company is routinely publishing advanced research in peer-reviewed journals and presenting at the major industry conferences.
Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with LifeExtension.com the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI.
In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named one of the global top 100 AI companies by CB Insights. Brief company video: https://www.youtube.com/watch?v=l62jlwgL3v8
www.Insilico.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.
Contact:
Samantha Park
P: 210.247.2426
F: 210.348.1003
E: samantha.park@frost.com
Share this article